Highlights of This Issue 1877

SPECIAL FEATURES

CCR Translations

1879 Can an Immune Checkpoint Inhibitor (Sometimes) Make Things Worse? Elad Sharon
See related article, p. 1920

CCR Perspectives in Regulatory Science and Policy

1882 FDA’s Approach to Regulating Biosimilars Steven J. Lemery, M. Stacey Ricci, Patricia Keegan, Amy E. McKe, and Richard Pazdur

CCR Drug Updates

1886 Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer Brant A. Inman, Thomas A. Longo, Sundhar Ramalingam, and Michael R. Harrison

Molecular Pathways

1891 Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer Amy Walz, Andrey Ugolkov, Sunandana Chandra, Alan Kozikowski, Benedito A. Carneiro, Thomas V. O’Halloran, Francis J. Giles, Daniel D. Billadeau, and Andrew P. Mazar

CANCER THERAPY: CLINICAL

1898 Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination Kristen A. Batic, Elizabeth A. Reap, Gary E. Archer, Luis Sanchez-Perez, Smita K. Nair, Robert J. Schmittling, Pam Norberg, Weihua Xie, James E. Herndon II, Patrick Healy, Roger E. McLendon, Allan H. Friedman, Henry S. Friedman, Peter Ansell, Mark McKe, and Ronald Levy


1920 Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 Stéphane Champiat, Laurent Dercele, Samy Ammari, Christophe Massard, Antoine Hollebeque, Sophie Postel-Vinay, Nathalie Chaput, Alexander Eggermont, Aurélien Marabelle, Jean-Charles Soria, and Charles Ferlet See related commentary, p. 1879


1937 Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer Suresh S. Ramalingam, Normand Blais, Julien Mazieres, Martin Reck, C. Michael Jones, Erzsébet Juhász, Laszlo Urban, Sergey Orlov, Fabrice Barlesi, Ebenezer Kio, Ulrich Reitholz, Qin Qin, Jiang Qian, Caroline Nickner, Juliann Dzitubinski, Hao Xiong, Peter Ansell, Mark McKe, Vincent Giranda, and Vera Gorbulova

1955 Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy

1967 The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population
Glenn Heller, Karim Fizazi, Robert McCormack, Arturo Molina, David MacLean, Iain J. Webb, Fred Saad, Johann S. de Bono, and Howard I. Scher

1974 A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy

1981 Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
James E. McDonald, Marcus M. Kessler, Michael W. Gardner, Amy F. Buros, James A. Ntambi, Sarah Waheed, Frits van Rhee, Maurizio Zangari, Christoph J. Heuck, Nathian Petty, Carolina Schinke, Sharmilan Thanendrarajan, Alan Mitchell, Antje Hoering, Bart Barlogie, Gareth J. Morgan, and Faith E. Davies

1988 RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Shumei McDonald, Vivek Subbiah, Erica Marchlik, Sheryl K. Elkin, Jennifer L. Carter, and Razelle Kurzrock

1998 Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum
Alicia Hulbert, Ignacio Juarez-Torres, Alejandro Stark, Chen Chen, Kristen Rodgers, Beverly Lee, Candace Griffin, Andrew Yang, Peng Huang, John Wrangle, Steven A. Belinsky, Tza-Huei Wang, Stephen C. Yang, Stephen B. Baylin, Malcolm V. Brock, and James G. Herman

2006 A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients

2019 Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study

1988 The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer
Yufang Ma, Lihong Wang, Leif R. Neitzel, Saddam N. Loganathan, Nan Tang, Lili Qin, Emily E. Crispi, Yan Guo, Stefan Knapp, B. Daniel Beauchamp, Ethan Lee, and Jalilang Wang

2038 A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon
Kang-Jian Zhang, Xiao-Fei Yin, Yuan-Qin Yang, Hui-Ling Li, Yan-Ni Xu, Lie-Ying Chen, Xia-Jun Liu, Su-Jing Yuan, Xian-Long Fang, Jing Xiao, Shuai Wu, Hai-Neng Xu, Liang Chu, Kanstantsin V. Katlinski, Yuliya V. Katlinskaya, Rong-Bing Guo, Guang-Wen Wei, Jan Cheng Wang, Xin-Yuan Liu, and Serge Y. Fuchs

2050 Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib
Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal Cancer
Qiaoyi Liang, Jonathan Chiu, Yingxuan Chen, Yanqin Huang, Akira Higashimori, Jingyuan Fang, Hassan Bitrin, Hassan Askotorab, Siew Chien Ng, Simon Siu Man Ng, Shu Zheng, Francis Ka Leung Chan, Joseph Jao Yu Sung, and Jun Yu

A Positive Feedback Loop of IncRNA-PVT1 and FOXM1 Facilitates Gastric Cancer Growth and Invasion
Mi-die Xu, Yiqin Wang, Weiwei Weng, Ping Wei, Peng Qi, Qinongyan Zhang, Cong Tan, Shu-juan Ni, Lei Dong, Yusi Yang, Wanrun Lin, Qinghua Xu, Dan Huang, Zhaohui Huang, Yuqing Ma, Wei Zhang, Weiqi Sheng, and Xiang Du

Integrative Systemic and Local Metabolomics with Impact on Survival in High-Grade Serous Ovarian Cancer
Anna Bachmayr-Heyda, Stefanie Aust, Katharina Auer, Samuel M. Meier, Klaus G. Schmetterer, Sabine Dekan, Christopher Gernez, and Dietmar Pils

Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases
Priyadharsini Nagarajan, Jonathan L. Curry, Jing Ning, Jin Piao, Carlos A. Torres-Cabala, Phyu P. Aung, Doina Ivan, Merrick I. Ross, Charles F. Levenback, Michael Frumovitz, Jeffrey E. Gershemwald, Michael A. Davies, Anais Malpica, Victor G. Prieto, and Michael T. Tetzlaff

Correction
Correction: Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1–Mediated Lipogenesis

2061 2065 2071 2081 2093 2105 2116 2127
ABOUT THE COVER

The cover shows a section of a primary tumor from mice harboring activated Braf and inactivated Pten in melanocytes that developed a genetically induced melanoma tumor. The staining shows aggressive tumor growth in animals treated with vehicle (as opposed to those treated with novel recombinant sIFN-I interferons). For details, see the article by Zhang and colleagues on page 2038 of this issue.